Clinical Trials Directory

Trials / Completed

CompletedNCT04713969

Neuro-immune Interactions and PPI

Duodenal Neuro-immune Interactions and Effects of PPI in Functional Dyspepsia

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
60 (actual)
Sponsor
Universitaire Ziekenhuizen KU Leuven · Academic / Other
Sex
All
Age
18 Years – 64 Years
Healthy volunteers
Accepted

Summary

Prospective interventional study on duodenal neuro-immune interactions in healthy volunteers and functional dyspepsia patients and the effects of PPI

Detailed description

Duodenal low-grade inflammation is frequently reported in functional dyspepsia (FD), while also neuronal and structural changes in duodenal submucosal ganglia have been described in FD patients. Proton pump inhibitors (PPI) are the first-line therapy in FD patients and are recently shown to have anti-inflammatory properties in FD. However, the exact mechanism of their anti-inflammatory action is unknow and their effect on duodenal nerve signalling remain unclear. In this prospective interventional study, FD patients will undergo study procedures before and after treatment with pantoprazole (Pantomed®) 40mg twice daily during 4 weeks, with a baseline comparison to healthy volunteers. This study aims to provide an in-deep characterization of the inflammatory infiltrate in the duodenum of FD patients, and to unravel the effect of PPI-therapy on neuronal signalling, duodenal inflammation and neuro-immune interactions in FD. Novel insights in the pathophysiology of FD, including the duodenal mucosal inflammation and impaired neuronal functioning, can provide a better understanding of this commonly and costly disorder. Moreover, these results will help to elucidate the anti-inflammatory effect of PPI, which will contribute to the discovery of predictive markers for therapeutic efficacy of PPI in FD.

Conditions

Interventions

TypeNameDescription
DRUGPantoprazole 40mgPantoprazole 40mg twice daily

Timeline

Start date
2021-03-31
Primary completion
2024-01-10
Completion
2024-09-23
First posted
2021-01-19
Last updated
2025-01-28

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT04713969. Inclusion in this directory is not an endorsement.